{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bozonnat A"],"funding":["Swiss National Science Foundation"],"pagination":["102679"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11245986"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["73"],"pubmed_abstract":["Background
Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, an anti-CCR4 monoclonal antibody, has recently been associated with increased progression-free survival in a randomized clinical trial in CTCL. We aimed to evaluate OS and prognostic factors in Sézary syndrome, including treatment with mogamulizumab, in a real-life setting.Methods
Data from patients with Sézary (ISCL/EORTC stage IV) and pre-Sézary (stage IIIB) syndrome diagnosed from 2000 to 2020 were obtained from 24 centers in Europe. Age, disease stage, plasma lactate dehydrogenases levels, blood eosinophilia at diagnosis, large-cell transformation and treatment received were analyzed in a multivariable Cox proportional hazard ratio model. This study has been regist"],"journal":["EClinicalMedicine"],"pubmed_title":["Real-life efficacy of immunotherapy for Sezary syndrome: a multicenter observational cohort study."],"pmcid":["PMC11245986"],"funding_grant_id":["200253"],"pubmed_authors":["Faiz S","Perier-Muzet M","Dobos G","Dereure O","Dalle S","de Masson A","Chasset F","Feldmeyer L","Montlahuc C","Bozonnat A","Ram-Wolff C","Amatore F","Moins-Teisserenc H","Quereux G","Michel C","Aubin F","Tedbirt B","Boulinguez S","Saiag P","Adamski H","Maubec E","Bouaziz JD","Resche-Rigon M","Grange F","Bejar C","Troin L","Serret-Larmande A","Montaudie H","Mourah S","Mortier L","Battistella M","Bonnet N","Viguier MA","Pham-Ledard A","Hainaut E","Beltraminelli H","Guenova E","Beylot-Barry M","D'Incan M","Bens G","Brunet-Possenti F","Templier I","Ingen-Housz-Oro S","Cutaneous Lymphomas French Study Group","Franck N","Donzel M","Joly P","Bagot M","Machet L"],"additional_accession":[]},"is_claimable":false,"name":"Real-life efficacy of immunotherapy for Sezary syndrome: a multicenter observational cohort study.","description":"Background
Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, an anti-CCR4 monoclonal antibody, has recently been associated with increased progression-free survival in a randomized clinical trial in CTCL. We aimed to evaluate OS and prognostic factors in Sézary syndrome, including treatment with mogamulizumab, in a real-life setting.Methods
Data from patients with Sézary (ISCL/EORTC stage IV) and pre-Sézary (stage IIIB) syndrome diagnosed from 2000 to 2020 were obtained from 24 centers in Europe. Age, disease stage, plasma lactate dehydrogenases levels, blood eosinophilia at diagnosis, large-cell transformation and treatment received were analyzed in a multivariable Cox proportional hazard ratio model. This study has been regist","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-03T01:09:53.674Z","creation":"2025-02-19T02:34:36.369Z"},"accession":"S-EPMC11245986","cross_references":{"pubmed":["39007062"],"doi":["10.1016/j.eclinm.2024.102679"]}}